PROT# INCB 18424-351: A Randomized, Double-Blind, Placebo-Controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Essential Thrombocythemi

Project: Research project

Project Details

StatusFinished
Effective start/end date11/3/09 → 10/2/18

Funding

  • PPD Development (INCB 18424-351 // INCB 18424-351)
  • Incyte Corporation (INCB 18424-351 // INCB 18424-351)